Literature DB >> 23313067

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

Ajai Chari1, Hadass Pri-Chen, Sundar Jagannath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23313067     DOI： 10.1016/j.clml.2012.12.010

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  10 in total

1.  The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.

Authors:  T R Rosean; V S Tompkins; A K Olivier; R Sompallae; L A Norian; H C Morse; T J Waldschmidt; S Janz
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

2.  Type I IFN gene delivery suppresses regulatory T cells within tumors.

Authors:  H Hashimoto; R Ueda; K Narumi; Y Heike; T Yoshida; K Aoki
Journal:  Cancer Gene Ther       Date:  2014-11-28       Impact factor: 5.987

3.  Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review.

Authors:  Peipei Xu; Hong Chu; Xiaoyan Shao; Ying Jiang; Chaoyang Guan; Ming Chen; Bing Chen
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

Review 4.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

Review 5.  IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Authors:  Nese Unver; Florencia McAllister
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-18       Impact factor: 7.638

Review 6.  Impact of interleukin-6 in hematological malignancies.

Authors:  Renate Burger
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

Review 7.  Siltuximab (CNTO 328): a promising option for human malignancies.

Authors:  Runzhe Chen; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

Review 8.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

Review 9.  Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.

Authors:  Tae-Hwe Heo; Joseph Wahler; Nanjoo Suh
Journal:  Oncotarget       Date:  2016-03-29

Review 10.  Emerging roles for the IL-6 family of cytokines in pancreatic cancer.

Authors:  Gemma van Duijneveldt; Michael D W Griffin; Tracy L Putoczki
Journal:  Clin Sci (Lond)       Date:  2020-08-28       Impact factor: 6.124
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.